Characteristics of IVF patients before treatment: where do we start?

Characteristics of IVF patients before treatment: where do we start?

Opis bibliograficzny
Główni autorzy:	Walsh, A, Collins, G, Walsh, D, Sills, E
Format:	Journal article
Wydane:	2010

Podobne zapisy

Pre-treatment preferences and characteristics among patients seeking in vitro fertilisation.
od: Walsh, A, i wsp.
Wydane: (2009)

Application of EU tissue and cell directive screening protocols to anonymous oocyte donors in western Ukraine: data from an Irish IVF programme.
od: Walsh, A, i wsp.
Wydane: (2010)

Bivariate analysis of basal serum anti-Mullerian hormone measurements and human blastocyst development after IVF.
od: Sills, E, i wsp.
Wydane: (2011)

Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
od: Lívia do Carmo Silva, i wsp.
Wydane: (2020-11-01)

A hole revolution, or are we back where we started?
od: Pooley, O
Wydane: (2006)

Pre-treatment preferences and characteristics among patients seeking in vitro fertilisation
od: Walsh David J, i wsp.
Wydane: (2009-12-01)

Recipient screening in IVF: First data from women undergoing anonymous oocyte donation in Dublin
od: Salma Umme, i wsp.
Wydane: (2011-04-01)

Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF
od: Sills E Scott, i wsp.
Wydane: (2011-12-01)

30 years of Gender Studies - where we started out and where we're headed
od: Helena Skálová
Wydane: (2022-01-01)

Ovarian serous adenocarcinoma identified during IVF: diagnostic approach, surgical management, and reproductive outcome
od: Gleeson Noreen C, i wsp.
Wydane: (2009-05-01)

IVF for premature ovarian failure: first reported births using oocytes donated from a twin sister
od: Sills Eric, i wsp.
Wydane: (2010-03-01)

A Five-Decade Text Mining Analysis of Cochlear Implant Research: Where We Started and Where We Are Heading
od: Idit Tessler, i wsp.
Wydane: (2023-10-01)

Orchesting Inclusive Evaluation in Schools. Where We Could Start?
od: Mª Amparo Calatayud
Wydane: (2019-12-01)

Optimisation of thrombolysis treatment: where to start?
od: Penaloza, M, i wsp.
Wydane: (2012)

Neural information processing in cognition: we start to understand the orchestra, but where is the conductor?
od: Guenther ePalm
Wydane: (2016-01-01)

Where should we start to improve pediatric heart transplantation outcomes?
od: Jinyoung Song
Wydane: (2021-02-01)

NISQ computing: where are we and where do we go?
od: Jonathan Wei Zhong Lau, i wsp.
Wydane: (2022-09-01)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
od: Omarini C, i wsp.
Wydane: (2018-01-01)

Lacrimal irrigation before intraocular surgery: Where are we today?
od: Akshay Gopinathan Nair
Wydane: (2024-10-01)

Vaccines against tuberculosis: where are we and where do we need to go?
od: Tom H M Ottenhoff, i wsp.
Wydane: (2012-01-01)

Entomology in South Africa: Where do we come from, where are we now and where are we going?
od: Jan H. Giliomee
Wydane: (2013-01-01)

Patient Blood Management: where to start?
od: Liana Maria Torres de Araujo Azi, i wsp.
Wydane: (2016-06-01)

Portrait of early science education in majority dual language learner classrooms: Where do we start?
od: Brooke Rumper, i wsp.
Wydane: (2021-10-01)

Where do we start? A baseline assessment for establishing health promoting schools in rural China
od: X. She, i wsp.
Wydane: (2014-09-01)

Where Do We Start? Building Consensus on Drivers of Health Sector Corruption in Nigeria and Ways to Address It
od: Obinna Onwujekwe, i wsp.
Wydane: (2020-07-01)

EdTech - Where Do I Start?
od: Nancy Caukin
Wydane: (2018-10-01)

Big change: what to do and where to start?
od: L. Guzenko
Wydane: (2005-10-01)

Ketogenic diet in the treatment of cancer – Where do we stand?
od: Daniela D. Weber, i wsp.
Wydane: (2020-03-01)

Start where you are /
od: Gardner, Chris., (Chris P.), i wsp.
Wydane: (2011)

Where it all started
od: Long Zhang, i wsp.
Wydane: (2023-04-01)

A descriptive study of oocyte, blood, and organ/tissue donation features among fertility patients in Ireland
od: Sills, E, i wsp.
Wydane: (2010)

A descriptive study of selected oocyte, blood and organ/tissue donation features among fertility patients in Ireland.
od: Sills, E, i wsp.
Wydane: (2010)

ColVI myopathies: where do we stand, where do we go?
od: Allamand Valérie, i wsp.
Wydane: (2011-09-01)

Treatment Of Diabetes In Bullous Pemphigoid Patients: Where Do We Stand?
od: Maria Alexandre, i wsp.
Wydane: (2023-01-01)

Where we are, where we are going
od: Teresa Bermejo-Vicedo, i wsp.
Wydane: (2020-03-01)

Where we are - where we are heading
od: Andreas Schaffner
Wydane: (2004-01-01)

“Guidelines Recommendations on the Treatment of Tricuspid Regurgitation. Where Are We and Where Do We Go With Transcatheter Valve Intervention”
od: Alec Vahanian, i wsp.
Wydane: (2018-04-01)

Therapeutic options for women with infertility before IVF
od: Н. О. Данкович, i wsp.
Wydane: (2017-04-01)

What are the Benefits of Diagnosing Endometriosis Before IVF?
od: Chii Ruey Tzeng
Wydane: (2023-12-01)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
od: Christopher G Laine, i wsp.
Wydane: (2020-01-01)